# EDGAR Filing Document

**Accession Number:** 0001818794
**File Stem:** 0001577014-26-000008
**Filing Date:** 2026-5
**Character Count:** 10176
**Document Hash:** 6b28cc2cfe6fbb5eb3bf0327ae0788a0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001577014-26-000008.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001577014-26-000008

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260504

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Rhodes Jason P
- **CENTRAL INDEX KEY:** 0001577014

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39509
- **FILM NUMBER:** 26949631

**MAIL ADDRESS:**
- **STREET 1:** C/O EPIZYME, INC.
- **STREET 2:** 400 TECHNOLOGY SQUARE, 4TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dyne Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001818794
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 364883909
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1560 TRAPELO ROAD
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** (781) 786-8230

**MAIL ADDRESS:**
- **STREET 1:** 1560 TRAPELO ROAD
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Rhodes Jason P<br><sub>(Last) (First) (Middle)</sub><br>C/O DYNE THERAPEUTICS, INC.<br>830 WINTER ST.<br><sub>(Street)</sub><br>WALTHAM, MA 02451<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Dyne Therapeutics, Inc. [ DYN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-04 |  | S<sup>(1)</sup> |  | 3136 | D | 18<sup>(2)</sup> | 1574270 | I | See footnote<sup>(3)</sup> |
| Common Stock | 2026-05-04 |  | S<sup>(1)</sup> |  | 6241 | D | 18<sup>(2)</sup> | 4933196 | I | See footnote<sup>(4)</sup> |
| Common Stock | 2026-05-04 |  | S<sup>(1)</sup> |  | 61 | D | 18<sup>(2)</sup> | 8450 | I | See footnote<sup>(5)</sup> |
| Common Stock | 2026-05-04 |  | S<sup>(1)</sup> |  | 2466 | D | 18<sup>(2)</sup> | 1156457 | I | See footnote<sup>(6)</sup> |
| Common Stock | 2026-05-05 |  | S<sup>(1)</sup> |  | 3056 | D | 18.03<sup>(7)</sup> | 1571214 | I | See footnote<sup>(3)</sup> |
| Common Stock | 2026-05-05 |  | S<sup>(1)</sup> |  | 6081 | D | 18.03<sup>(7)</sup> | 4927115 | I | See footnote<sup>(4)</sup> |
| Common Stock | 2026-05-05 |  | S<sup>(1)</sup> |  | 60 | D | 18.03<sup>(7)</sup> | 8390 | I | See footnote<sup>(5)</sup> |
| Common Stock | 2026-05-05 |  | S<sup>(1)</sup> |  | 2403 | D | 18.03<sup>(7)</sup> | 1154054 | I | See footnote<sup>(6)</sup> |
| Common Stock | 2026-05-06 |  | S<sup>(1)</sup> |  | 21926 | D | 18.18<sup>(8)</sup> | 1549288 | I | See footnote<sup>(3)</sup> |
| Common Stock | 2026-05-06 |  | S<sup>(1)</sup> |  | 43621 | D | 18.18<sup>(8)</sup> | 4883494 | I | See footnote<sup>(4)</sup> |
| Common Stock | 2026-05-06 |  | S<sup>(1)</sup> |  | 428 | D | 18.18<sup>(8)</sup> | 7962 | I | See footnote<sup>(5)</sup> |
| Common Stock | 2026-05-06 |  | S<sup>(1)</sup> |  | 17244 | D | 18.18<sup>(8)</sup> | 1136810 | I | See footnote<sup>(6)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.

(2) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0206 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

(3) The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.

(4) The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.

(5) The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any.

(6) The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.

(7) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.0831 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

(8) The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

**Signature:** /s/ Ommer Chohan, Attorney-in-Fact  
**Date:** 2026-05-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**